We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel X-Linked Intellectual Disability Genes Identified

By LabMedica International staff writers
Posted on 24 Feb 2015
A novel group of genes on the X-chromosome that when mutated lead to the mental disorder X-linked intellectual disability (XLID) have been added to list of more than a 100 such genes that had been identified previously.

XLID is a generalized neurodevelopmental disorder characterized by significantly impaired intellectual and adaptive functioning. More...
It is defined by an IQ score below 70 in addition to deficits in two or more adaptive behaviors that affect everyday general living. The syndrome is caused by mutations on the X-chromosome. Since males have only one X-chromosome and the syndrome is passed on in a recessive manner, the disorder mainly occurs in boys. Over the past 20 years more than 100 X-chromosome genes linked to XLID have been found. Nonetheless, intellectual disabilities that map to the X-chromosome remain unresolved in a large number of families, which suggests that more XLID genes or loci are yet to be identified.

To identify more XLID-linked genes investigators at the Max Planck Institute for Molecular Genetics (Berlin, Germany) employed massively parallel sequencing of all X-chromosome exons in the index males of 405 families with XLID of unknown origin. In total, 745 X-chromosomal genes were screened.

Results revealed that 80 families (20%) carried pathogenic variants in established XLID genes. In 19 families, the investigators detected likely causative protein truncating and missense variants in seven novel and validated XLID genes (CLCN4, CNKSR2, FRMPD4, KLHL15, LAS1L, RLIM, and USP27X) and potentially deleterious variants in two novel candidate XLID genes (CDK16 and TAF1). Furthermore, they showed that the CLCN4 and CNKSR2 variants impaired protein functions as indicated by electrophysiological studies and altered differentiation of cultured primary neurons from mice lacking CLCN4 or after mRNA knock-down.

"In addition to known disease-related genes, we have discovered seven novel genes as the cause of X-linked intellectual disability and analyzed what signaling pathways in the cells each protein is involved in," said senior author Dr. Vera Kalscheuer, professor of human molecular genetics at the Max Planck Institute for Molecular Genetics. "The clinical presentation and severity of the disorder depend on the responsible gene and the nature of the mutation."

The study was published in the February 3, 2015, online edition of the journal Molecular Psychiatry.

Related Links:

Max Planck Institute for Molecular Genetics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Urine Analyzer
respons® UDS100
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.